Changzhou Qianhong Biopharma CO.,LTD

Equities

002550

CNE100001070

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-23 pm EDT 5-day change 1st Jan Change
5.8 CNY +0.87% Intraday chart for Changzhou Qianhong Biopharma CO.,LTD 0.00% -1.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 CI
Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for the Year 2023 CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on January 3, 2024. CI
Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback announced on January 3, 2024 has closed with 25,000,000 shares, representing 1.95% for CNY 140.76 million. CI
Changzhou Qianhong Biopharma CO.,LTD Approves Board Elections CI
Changzhou Qianhong Biopharma CO.,LTD announces an Equity Buyback for CNY 170 million worth of its shares. CI
Changzhou Qianhong Biopharma CO.,LTD authorizes a Buyback Plan. CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Changzhou Qianhong Biopharma CO.,LTD(XSEC:002550) added to S&P Global BMI Index CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Changzhou Qianhong Biopharma Co.,Ltd Announces Cash Dividend on A Shares for 2022, Payable on May 26, 2023 CI
Changzhou Qianhong Biopharma CO.,LTD Approves Cash Dividend for 2022 CI
Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on April 15, 2023. CI
Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback announced on April 15, 2023 has closed with 5,000,000 shares, representing 0.39% for CNY 30.09 million. CI
Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for 2022 CI
Changzhou Qianhong Biopharma CO.,LTD announces an Equity Buyback for CNY 34 million worth of its shares. CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Changzhou Qianhong Biopharma Co.,Ltd authorizes a Buyback Plan. CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Qianhong Bio Pharma to Invest $85 Million in New Drug Production Base MT
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2021, Payable on 25 May 2022 CI
Changzhou Qianhong Biopharma Co.,Ltd Approves Dividend for 2021 CI
Chart Changzhou Qianhong Biopharma CO.,LTD
More charts
Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.8 CNY
Average target price
6.12 CNY
Spread / Average Target
+5.52%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002550 Stock
  4. News Changzhou Qianhong Biopharma CO.,LTD
  5. Qianhong Bio Pharma to Invest $85 Million in New Drug Production Base